<DOC>
	<DOCNO>NCT03010072</DOCNO>
	<brief_summary>This single-center , prospective , open-label , control , randomize , cross-over study 34 prevalent end-stage renal disease patient chronic hemodialysis treatment hyperphosphatemia .</brief_summary>
	<brief_title>The Effect Phosphate Lowering Using Sucroferric Oxyhydroxide ( PA21 ) Calcification Propensity Serum</brief_title>
	<detailed_description>Patients randomize 1:1 ratio either receive low-dose ( 250mg/d ) PA-21 follow high-dose ( 2000mg/d ) PA-21 ( sequence A-B ) receive high-dose PA21 follow low-dose PA21 ( sequence B-A ) washout-phases . An open label design sub-therapeutic dose PA21 control treatment choose create convince placebo PA21 feasible . The study start two study visit 2nd 3rd dialysis session week , dialysis patient still treat standard care establish baseline value ( duration : 0.5 week ) . Next initial run-in wash-out phase , phosphate binder take patient standard care treatment discontinue phosphate binder introduce . Consequently , PA21 treatment ( high dose/low dose ) phase , follow wash-out phase , follow another PA21 treatment ( high dose/low dose ) phase , follow final wash-out phase . Each study phase , include wash-out phase well low-dose high-dose treatment phase 14 day duration . Patients follow 10.5 week randomization last study visit final wash-out phase .</detailed_description>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Prevalent patient ( ≥ 3 month dialysis ) treat thrice weekly hemodialysis ( HD ) hemodiafiltration ( HDF ) Hyperphosphatemia ( serum phosphate &gt; upper limit normal within last 3 month ) current phosphate binder use No use constant dose vitamin D and/or calcimimetics ≥2 week Allergy sucroferric oxyhydroxide ( PA21 ) , ingredient Velphoro ironmedication Current history calciphylaxis ( calcific uremic arteriolopathy CUA ) parathormone &gt; 800 pg/ml Parathyreoidektomie plan expect Significant GI hepatic disorder Hypercalcemia ( total serum calcium &gt; 2.6 mmol/l ) screen Antacids contain aluminum , calcium , magnesium bicarbonate Oral iron treatments/supplements Pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>